EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Blood TRPC6 mRNA as a biomarker for Alzheimer's disease: a nationwide, multicenter study in China

Mei Pu, Yutong Wen, Yujing Chen, Jing Wang, Xiaoli Pan, Gang Wang, Xia Li, Guihong Wang, Chuantao Zuo, Jiong Shi, Liliang Zhu, Jie Wu, Rujing Ren, Xiaoqin Cheng, Shaowei Zhang, Jintao Wang, Shujing Liu, Ling Li, Fei Huang, Ding Ding, Yihui Guan, Chunjiu Zhong, Qianhua Zhao, Yizheng Wang

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)

DOI: 10.1002/dad2.70433 ↗
AbstractBibliografische Angaben

Abstract

Abstract INTRODUCTION Accessible blood‐based biomarkers remain needed for Alzheimer's disease (AD) screening and diagnosis. We investigated whether blood transient receptor potential canonical 6 (TRPC6) could serve as a potential biomarker for AD. METHODS We enrolled 1254 individuals, including 366 patients with AD, 735 cognitively unimpaired (CU) individuals, and 153 individuals with non‐AD neurological disorders. All patients with AD were confirmed to be amyloid beta positive (Aβ+) by Aβ positron emission tomography (PET). Blood TRPC6 messenger RNA (mRNA) levels were measured in all participants. In a subset, Aβ PET imaging and plasma biomarker assessments were performed. RESULTS Blood TRPC6 mRNA levels differed significantly among the CU, AD, and non‐AD groups, with the lowest levels observed in patients with AD. TRPC6 mRNA levels were associated with regional Aβ deposition and showed diagnostic performance comparable to several established plasma biomarkers, although slightly inferior to phosphorylated tau 217. DISCUSSION Blood TRPC6 mRNA is markedly reduced in AD and may represent an accessible and clinically relevant blood biomarker for AD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →